Supplementary Data

**Supplemental Table S1.** Summary of MEDI-573 IC50 on the proliferation of sarcoma cell lines with or without exogenously added IGF-1 or IGF-2. All IC50 values were generated through nonlinear regression curve fitting using Prism Graph Pad software.

|  |  |  |  |
| --- | --- | --- | --- |
| **Sarcoma Subtype** | **Cell Line** | **No IGF added** | **Exogenous IGF added** |
| **IC50 (g/ml)** | **IGF-1 stimulated IC50 (g/ml)** | **IGF-2 stimulated IC50 (g/ml)** |
| **Ewing’s Sarcoma** | RD-ES | 0.94 g/ml | 6.1 g/ml | 0.29 g/ml |
| SK-ES-1 | 0.25 g/ml | 3.1 g/ml | 3.1 g/ml |
| TC-71 | 0.91 g/ml | 3.5 g/ml | 0.81 g/ml |
| **Rhabodomyosarcoma** | SJCRH30 | 0.48 g/ml | ND | ND |
| RD | 30% inhibition | no induction | no induction |
| Hs729 | Inactive | ND | ND |
| **Osteosarcoma** | SJSA-1 | 30% inhibition | no induction | no induction |
| KHOS | Inactive | no induction | no induction |
| MG-63 | inactive | 33.4 g/ml | 5.2 g/ml |
| SAOS2 | inactive | 26.5 g/ml | 5.4 g/ml |

**Supplemental Figure S1.** Effect of MEDI-573 in combination with AZD2014 on SJSA-1 tumor growth *in vivo*. SJSA-1 xenografts were administered either MEDI-573 i.p. twice weekly or AZD2014 by oral gavage daily as single agents or in combination for the duration of study.

